What’s the reality for CDK4/6 inhibitors: Clinical trials or real‐world evidence?
Sign Up to like & getrecommendations! Published in 2023 at "Cancer"
DOI: 10.1002/cncr.34672
Abstract: represented in clinical trials, and to frame opportunities to improve patient outcomes. As a result, RWE is not a panacea to resolve all residual uncertainties from clinical trial results, and well ‐ adjusted multivariate analysis… read more here.
Keywords: health; clinical trials; cdk4 inhibitors; reality cdk4 ... See more keywords
Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
Sign Up to like & getrecommendations! Published in 2020 at "Current Oncology Reports"
DOI: 10.1007/s11912-020-00917-8
Abstract: Purpose of Review Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have revolutionized the treatment landscape for patients with hormone receptor-positive (HR+) and HER2-negative (HER2−) metastatic breast cancer (MBC). However, optimal therapy after CDK4/6 inhibitors is… read more here.
Keywords: cdk4 inhibitor; cdk4; breast cancer; cdk4 inhibitors ... See more keywords
Cyclin-dependent Kinases 4/6 Inhibitors in Neuroendocrine Neoplasms: from Bench to Bedside
Sign Up to like & getrecommendations! Published in 2022 at "Current Oncology Reports"
DOI: 10.1007/s11912-022-01251-x
Abstract: Cyclin-dependent kinases (CDKs) are key regulators that play an important role in cell division. Palbociclib, ribociclib and abemaciclib showed significant antitumor activity in several malignancies and, recently, also a myeloprotective effect for trilaciclib when added… read more here.
Keywords: neuroendocrine neoplasms; dependent kinases; cdk4 inhibitors; inhibitors neuroendocrine ... See more keywords
Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: Palbociclib and ribociclib.
Sign Up to like & getrecommendations! Published in 2017 at "Breast"
DOI: 10.1016/j.breast.2017.05.016
Abstract: PURPOSE Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors such as palbociclib and ribociclib are associated with distinct adverse effects (AEs) compared to other targeted therapies. This meta-analysis of clinical trials summarizes these agents' toxicity profile.… read more here.
Keywords: palbociclib ribociclib; analysis; toxicity; cdk4 inhibitors ... See more keywords
CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer cell"
DOI: 10.1016/j.ccell.2018.03.023
Abstract: CDK4/6 inhibitors are among a new generation of therapeutics. Building upon the striking success of the combination of CDK4/6 inhibitors and the hormone receptor antagonist letrozole in breast cancer, many other combinations have recently entered… read more here.
Keywords: may simple; inhibitors mechanism; cdk4; cdk4 inhibitors ... See more keywords
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer cell"
DOI: 10.1016/j.ccell.2018.11.006
Abstract: Cyclin dependent kinase 4/6 (CDK4/6) inhibitors (CDK4/6i) are effective in breast cancer; however, drug resistance is frequently encountered and poorly understood. We conducted a genomic analysis of 348 estrogen receptor-positive (ER+) breast cancers treated with… read more here.
Keywords: tumor suppressor; resistance cdk4; cdk4 inhibitors; hippo pathway ... See more keywords
CDK4/6 Inhibitors in Combination With Hormone Therapy for HR+/HER2− Advanced Breast Cancer: A Systematic Review and Meta‐analysis of Randomized Controlled Trials
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Breast Cancer"
DOI: 10.1016/j.clbc.2018.04.017
Abstract: Background This meta‐analysis of randomized controlled trials aimed to comprehensively assess the efficacy and toxicity of cyclin‐dependent kinase (CDK) 4/6 inhibitors in advanced breast cancer (ABC) with hormone‐receptor positive (HR+) and human epidermal growth factor… read more here.
Keywords: cdk4 inhibitors; hormone therapy; breast cancer; meta analysis ... See more keywords
Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical breast cancer"
DOI: 10.1016/j.clbc.2021.10.002
Abstract: PURPOSE Everolimus with exemestane (EVE+EXE) was FDA-approved to treat metastatic hormone receptor-positive breast cancer (mHRBC) based on BOLERO-2. However, none of those patients received prior CDK4/6 inhibitors. The purpose of this study is to evaluate… read more here.
Keywords: prior cdk4; eve exe; cdk4; breast cancer ... See more keywords
Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer treatment reviews"
DOI: 10.1016/j.ctrv.2019.01.006
Abstract: CDK4/6 inhibitors are a new class of anticancer drugs used for the treatment of women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.… read more here.
Keywords: drug interactions; breast cancer; drug; cdk4 inhibitors ... See more keywords
CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Cancer treatment reviews"
DOI: 10.1016/j.ctrv.2020.102136
Abstract: CDK4/6 inhibitors (CDK4/6i) in combination with endocrine therapy are the mainstay of treatment for patients with hormone receptor-positive, HER2 negative (HR+/HER2neg) metastatic breast cancer. However, resistance - either de novo or acquired - invariably occurs,… read more here.
Keywords: hormone receptor; response; receptor positive; treatment ... See more keywords
Senescence as a therapeutically relevant response to CDK4/6 inhibitors
Sign Up to like & getrecommendations! Published in 2020 at "Oncogene"
DOI: 10.1038/s41388-020-1354-9
Abstract: Cyclin-dependent kinases 4 and 6 (CDK4/6) phosphorylate and inhibit retinoblastoma (RB) family proteins. Hyperphosphorylated RB releases E2F transcription factors, activating a transcriptional program that initiates S phase. Due to the critical role that this pathway… read more here.
Keywords: response; senescence therapeutically; senescence; therapeutically relevant ... See more keywords